Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.42 |
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA4 | P22748 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130391 | 1.00 | CA1 (0.42) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL15625954 | 0.81 | CA1 (0.53) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL21034463 | 0.78 | FAAH (0.42) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL21034464 | 0.78 | FAAH (0.42) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL538865 | 0.77 | ALDH1A1 (0.56) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL3107844 | 0.77 | ALDH1A1 (0.56) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL902931 | 0.77 | ALDH1A1 (0.56) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL7121377 | 0.77 | L3MBTL1 (0.59) | CA1CA2CA4CA9L3MBTL1 | |
| SCHEMBL7121380 | 0.77 | L3MBTL1 (0.59) | CA1CA2CA4CA9L3MBTL1 | |
| SCHEMBL7130397 | 0.76 | SMN1; SMN2 (0.46) | CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153771-A1 | Large scale synthesis of optically pure aziridines | LEXICON PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153771-A1 | Large scale synthesis of optically pure aziridines | QDPR, AZI2, NISCH | CA1 3495/4885CA2 2934/4885CA4 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.